  |
 | Up a level |
Rugo, Hope S. and Barve, Abhijit and Waller, Cornelius F. and Hernandez-Bronchud, Miguel and Herson, Jay and Yuan, Jinyu and Sharma, Rajiv and Baczkowski, Mark and Kothekar, Mudgal and Loganathan, Subramanian and Manikhas, Alexey and Bondarenko, Igor and Mukhametshina, Guzel and Nemsadze, Gia and Parra, Joseph D and Abesamis Tiambeng, Maria Luisa T. and Baramidze, Kakhaber and Akewanlop, Charuwan and Vynnychenko, Ihor and Sriuranpong, Virote and Mamillapalli, Gopichand and Ray, Sirshendu and Ruiz, Eduardo P Yanez and Pennella, Eduardo (2017) Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. A Randomized Clinical Trial. JAMA, 317 (1). pp. 37-47.
Rugo, Hope S. and Barve, Abhijit and Waller, Cornelius F. and Hernandez-Bronchud, Miguel and Herson, Jay and Yuan, Jinyu and Manikhas, Alexey and Bondarenko, Igor and Mukhametshina, Guzel and Nemsadze, Gia and Parra, Joseph D. and Tiambeng, Maria Luisa T. Abesamis and Baramidze, Kakhaber and Akewanlop, Charuwan and Vynnychenko, Ihor and Sriuranpong, Virote and Manillapalli, Gopichand and Ray, Sirshendu and Ruiz, Eduardo Patricio Yanez and Pennella, Eduardo J (2016) Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. Journal of Clinical Oncology, Vol 34 (18_sup). P.-LBA503. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)
